| Brand Name: | Ansulet ASP 30/70 |
| Generic: | Insulin Aspart |
| Weight: | 100 unit/ml |
| Type: | SC Injection |
| Therapeutic Class: | Rapid Acting Insulin |
| Manufacturer: | Aristopharma Ltd. |
| Price: | 581.00 |
| Last Updated: | 2020-11-21 18:15:00 |
Ansulet ASP 30/70 SC Injection contains Insulin Aspart. Ansulet ASP 30/70 uses:
Ansulet ASP 30/70 SC Injection is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.
Ansulet ASP 30/70 SC Injection contains Insulin Aspart 100 unit/ml. Ansulet ASP 30/70 doses:
Usual range: 0.5-1 units/kg/day. When used in a meal-related SC inj treatment regimen, insulin aspart may provide 50-70% of total insulin requirement with the remainder provided by an intermediate-acting or long-acting insulinThe dosage of insulin aspart must be individualized
Subcutaneous injection: insulin aspart should generally be given immediately (within 5-10 minutes) prior to the start of a meal
Use in pumps: Change the insulin aspart in the reservoir at least every 6 days, change the infusion set, and the infusion set insertion site at least every 3 daysinsulin aspart should not be mixed with other insulins or with a diluent when it is used in the pump
Intravenous use: Insulin aspart should be used at concentrations from 0.05 U/mL to 1.0 U/mL insulin aspart in infusion systems using polypropylene infusion bags. insulin aspart has been shown to be stable in infusion fluids such as 0.9% sodium chloride
Administer 5-10 min before meal
Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatrophy or lipohypertrophy with SC Inj (rotate Inj site).
The primary activity of Ansulet ASP 30/70 SC Injection is the regulation of glucose metabolism. Ansulet ASP 30/70 SC Injection bind to the insulin receptors on muscle and fat cells and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver.
Renal or hepatic impairment; pregnancy; lactation. Transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections; hypokalaemia.
Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by β-blockers, clonidine.
Pregnancy Category B. All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. Insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. Careful monitoring of glucose control is essential in these patients. Therefore, female patients should be advised to tell their physician if they intend to become, or if they become pregnant while taking insulin aspart.
Insulin Ansulet ASP 30/70 SC Injection is contraindicated-
Renal Impairment: Decreased dose may be necessary.
Hepatic Impairment: Decreased dose may be necessary.
Ansulet ASP 30/70 SC Injection price in Bangladesh 581.00